Press Room

Event

CSF Europe 2024 - Compaction Simulation Forum

Start
Tuesday, June 04, 2024 - 16:49
End
Thursday, June 06, 2024 - 18:00
Location: Dublin, Ireland
CSF Conference João Henriques speaker | Hovione

CSF Workshop: Overcoming The Challenge of Poorly Soluble Drugs

This workshop delves into the complexities surrounding the formulation of poorly soluble drugs, a prevalent concern affecting a significant percentage of active pharmaceutical ingredients. Explore the scientific nuances of amorphous forms and their role in amorphous solid dispersions (ASDs), offering insights into enhanced solubility and dissolution. 

Our expert, João Henriques, Director, Oral Drug Product Development will lead the Workshop Session: Process Development and Scale-Up of Spray Drying

Join the session for an academic exploration where knowledge converges with scientific rigor, providing a thorough understanding of the formulation intricacies of poorly soluble drugs.
 
Key learnings:

  • Expand on your foundations and principles of spray drying for ASDs, from lab-scale development tools to the scale-up of processes and gain valuable insights on how ASDs improve the solubility and bioavailability of poorly soluble drugs.
  • Overcome solubility challenges with the best scale-up science, utilizing mechanistic and statistical modeling to delve into the impact of spray drying conditions and material attributes on downstream processing while leveraging our extensive expertise to ensure success from lab-scale to commercialization.

 

Do you want to know how Hovione can support your project? Schedule a meeting today.

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

 

 

 

 

Learn more about CSF Europe.

 

 

Also in the Press Room

See All

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News
Hovione commitment to setting SBTs in line with the Paris Agreement

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024

The partnership with Higuchi forms part of Hovione´s global expansion plans and marks a significant milestone in advancing Hovione's presence in the Japanese market.    Under the terms of the agreement, Higuchi will promote Hovione's pharmaceutical service business throughout Japan, using their extensive experience to enhance brand visibility and attract new clientele across the Japanese pharmaceutical landscape.  “This strategic collaboration underscores Hovione's dedication to delivering innovative solutions and exceptional service to its customers,” said Yuken Kyoyama. “Our partnership with Higuchi will help to show customers in Japan how Hovione can meet their needs.”    Learn more about our business in Japan and visit our website hovione.co.jp    

News
Hovione proudly announces its collaborative venture with Higuchi.

Hovione forges strategic partnership with Higuchi to further strengthen its presence in Japan

Jul 04, 2024

Following the creation of offices in Shanghai and Beijing, Hovione is pleased to announce the launch of its new website in Mandarin. This dedicated platform will enhance Hovione´s presence in China, offering tailored contents to better serve customers in this important market. The new site will provide comprehensive information about Hovione´s products and services, ensuring that Chinese clients have easier access to the innovative solutions and support that Hovione is renowned for worldwide.   “The launch of the Hovione Chinese website underscores our commitment to customers in China,” said Ms. Jackie Liu, Country Head, China. “By delivering localized content and support, we aim to foster stronger partnerships and drive mutual growth in this market. Our team of experts is fully committed to understanding and addressing our clients´ unique challenges with agility and precision.” Visit us at www.hovione.com.cn    

News
Hovione is closer to its customers with a new website in Mandarin

Hovione launches new website for the Chinese Market

Jun 14, 2024

Also in Events

See All